Comprehensive gene analysis for the specimen of pancreatic cancer obtained by EUS-FNA
Not Applicable
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000030757
- Lead Sponsor
- Kindai University
- Brief Summary
The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Presence of interveneous vesseles in the puncture line during EUS-FNA 2. High risk of bleeding 3. Difficulty of performing EUS 4. Without informed consent 5. Deemed ineligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acquision rate of the specimen obtained by EUS-FNA for comprehensive gene analysis.
- Secondary Outcome Measures
Name Time Method